Cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
==== Serotonin–norepinephrine reuptake inhibitors (SNRIs) ==== Duloxetine (Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve) – serotonin–norepinephrine reuptake inhibitor (SNRI) [40] Venlafaxine (Dobupal; Efexor XR; Effexor; Effexor XR; Elafax; WY-45030; WY-45651; WY-45655) – serotonin–norepinephrine reuptake inhibitor (SNRI) [41]
=== Elimination === Testosterone and its metabolites are eliminated in urine. It is excreted mainly as androsterone glucuronide and etiocholanolone glucuronide. It is also excreted to a small extent as other conjugates such as testosterone glucuronide (1%), testosterone sulfate (0.03%), and androstanediol glucuronides. Only a very small amount of testosterone (less than 0.01%) is found unchanged in the urine.
Various medications are approved for treating obesity with varying rates of weight loss between 3-21%, but weight regain is very common after discontinuation. Medications are recommended to be used only in combination with lifestyle changes. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year.
Sources: en.wikipedia.org
=== Aston Medal === In 1987 the society announce the establishment of the Aston Medal to be awarded to “individuals deserving special recognition by reason of their outstanding contributions to knowledge in the biological, chemical, engineering, mathematical, medical, or physical sciences relating directly to mass spectrometry”.
Cantrell had the band's engineer, Paul Figueroa, come in to his house and record a lot of his vocals and solos there. The band finished recording the album at the Henson Recording Studios in Los Angeles. Cantrell also said he expected the album to be released "probably sometime this summer." At the press room of the Rock and Roll Hall of Fame Induction Ceremony on April 14, 2018, Cantrell revealed that Alice in Chains had just signed with BMG, and that they had finished mixing their new album. Alice in Chains did not perform live in 2017. The band performed their first concert since October 2016 at the House of Blues in Boston on April 28, 2018. In May 2018, Alice in Chains headlined the festivals Carolina Rebellion, Lunatic Luau, Pointfest, Northern Invasion, the WMMR BBQ festival in Philadelphia, and the Rock on the Range festival in Columbus, Ohio on May 18, 2018, in which they paid tribute to Chris Cornell on the first anniversary of his death covering two Soundgarden songs to close their set, "Hunted Down" and "Boot Camp", respectively. At the end of the show, the lights on stage spelled out "CC" for Chris Cornell and "SG" for Soundgarden as feedback rang out. The band started their European tour in June 2018, and headlined the Tons Of Rock Festival in Norway alongside Ozzy Osbourne and Helloween. Alice in Chains are also scheduled to headline KISW's Pain in the Grass festival in August 2018. The band released a new single, "The One You Know", via Spotify, Amazon and iTunes on May 3, 2018. A music video directed by Adam Mason was released on YouTube the same day.
Several scandals affected Uribe's administration; the Colombian parapolitics scandal expanded during his second term, involving numerous members of the administration's ruling coalition. Many pro-government lawmakers, such as the President's cousin Mario Uribe, were also investigated for their possible ties to paramilitary organizations. At the end of 2007, FARC agreed to release former senator Consuelo González, politician Clara Rojas, and her son Emmanuel, born in captivity after a relationship with one of her captors. Operation Emmanuel was proposed and set up by Venezuelan President Hugo Chávez, with the permission of the Colombian government. The mission was approved on December 26; however, on December 31, FARC claimed that the hostage release had been delayed because of Colombian military operations. At the same time, Colombian President Álvaro Uribe indicated that FARC had not freed the three hostages because Emmanuel may not be in their hands anymore. Two FARC gunmen were taken prisoner. Colombian authorities added that a boy matching Emmanuel's description had been taken to a hospital in San José del Guaviare in June 2005. The child was in poor condition; one of his arms was hurt, he had severe malnutrition, and he had diseases that are commonly suffered in the jungle. Having been evidently mistreated, the boy was later sent to a foster home in Bogotá, and DNA tests were announced to confirm his identity.
Sources: en.wikipedia.org
=== Feminist collages === In February 2019, she began posting collages which featured brief feminist slogans in public spaces across France, particularly in Paris and Marseille. Her collages are composed of black letters painted one by one on white sheets. Her first slogan was "Since I was 13, men have commented on my physical appearance in the street."
== Mechanisms of Algicidal Bacteria == Various mechanisms are employed by bacteria to facilitate their algicidal processes. There are two established methods of algicidal activity: direct and indirect. However, some bacteria are capable of both. Some of these mechanisms are enhanced under different environmental conditions, such as varying nutrient availability.
27 December – The Met Office issues a yellow weather warning for rain over Hogmanay, starting on 30 December and lasting over the New Year. Public Health Scotland says health services in Scotland are under "acute pressure" following a surge in flu cases. Caledonian MacBrayne is forced to reduce the number of passengers allowed on the MV Isle of Mull to 45 per journey after failing a safety check. 29 December – Emergency services searching for keen wild swimmer Ian Napier, missing from the Scousburgh Bay area since 27 December, find a body in the sea near Shetland. 30 December – Edinburgh's Hogmanay celebrations are cancelled amid weather warnings for heavy rain, high winds and snow over the New Year. 2025 New Year Honours: Among those to be recognised in the New Year Honours are broadcaster Jackie Bird (MBE), footballer and broadcaster Alan Hansen (MBE) and Olympic swimmer Duncan Scott (OBE).
== Clinical significance == The gastrointestinal wall can be affected in a number of conditions. An ulcer is something that's eroded through the epithelium of the wall. Ulcers that affect the tract include peptic ulcers and perforated ulcer is one that has eroded completely through the layers. The gastrointestinal wall is inflamed in a number of conditions. This is called esophagitis, gastritis, duodenitis, ileitis, and colitis depending on the parts affected. It can be due to infections or other conditions, including coeliac disease, and inflammatory bowel disease affects the layers of the gastrointestinal tract in different ways. Ulcerative colitis involves the colonic mucosa. Crohn's disease may produce inflammation in all layers in any part of the gastrointestinal tract and so can result in transmural fistulae. Invasion of tumours through the layers of the gastrointestinal wall is used in staging of tumour spread. This affects treatment and prognosis. The normal thickness of the small intestinal wall is 3–5 mm, and 1–5 mm in the large intestine. Focal, irregular and asymmetrical gastrointestinal wall thickening suggests a malignancy. Segmental or diffuse gastrointestinal wall thickening is most often due to ischemic, inflammatory or infectious disease.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.